Daily Endocrinology Research Analysis
Three impactful endocrinology papers stood out: a multicenter longitudinal cohort defined cumulative blood pressure load as a strong predictor of arterial stiffness progression and diabetic kidney disease; a global modeling analysis updated the 2025 and 2040 burden of type 1 diabetes; and a mechanistic study identified a novel NR3C1 nonsense mutation linking glucocorticoid resistance to male infertility via STUB1-mediated degradation.
Summary
Three impactful endocrinology papers stood out: a multicenter longitudinal cohort defined cumulative blood pressure load as a strong predictor of arterial stiffness progression and diabetic kidney disease; a global modeling analysis updated the 2025 and 2040 burden of type 1 diabetes; and a mechanistic study identified a novel NR3C1 nonsense mutation linking glucocorticoid resistance to male infertility via STUB1-mediated degradation.
Research Themes
- Risk stratification for diabetic complications using longitudinal hemodynamic exposure
- Global epidemiology and health systems planning in type 1 diabetes
- Genetic and proteostatic mechanisms in glucocorticoid resistance and reproductive endocrinology
Selected Articles
1. Cumulative blood pressure load as a predictor of arterial stiffness progression and incident diabetic kidney disease: a multicenter longitudinal study.
In 18,168 adults with type 2 diabetes followed for a mean 3.5 years, cumulative systolic blood pressure load improved prediction of both brachial-ankle pulse wave velocity progression and incident diabetic kidney disease. Models using an SBP target of <120 mmHg to calculate cumulative load showed the best predictive performance.
Impact: Defines a practical, integrative hemodynamic metric that enhances risk stratification for vascular and renal complications beyond traditional single-time blood pressure readings.
Clinical Implications: Consider incorporating cumulative SBP load (preferably using a <120 mmHg threshold) into longitudinal risk assessment for type 2 diabetes to refine targets and prioritize intensive BP management strategies for patients at higher risk.
Key Findings
- Cumulative SBP load significantly improved prediction of arterial stiffness progression (ba-PWV) and incident DKD over a mean 3.5-year follow-up.
- Among 18,168 participants, median ba-PWV increased by 0.19 m/s per year and 25.6% developed DKD.
- Using an SBP target of <120 mmHg to calculate cumulative load yielded the best predictive performance compared with higher targets.
Methodological Strengths
- Large multicenter longitudinal cohort with standardized outcomes (ba-PWV, eGFR-based DKD).
- Comparative evaluation across clinically relevant SBP targets to optimize predictive modeling.
Limitations
- Observational design limits causal inference regarding BP lowering to <120 mmHg and outcomes.
- Details of discrimination metrics (e.g., C-statistic, adjusted R) are truncated in the abstract; full methods are needed to appraise model calibration.
Future Directions: Prospective intervention trials testing BP targets and incorporating cumulative BP load as a mechanistic and surrogate endpoint; external validation across diverse ethnicities and care settings.
BACKGROUND: Elevated blood pressure (BP) is a key contributor to the progression of arterial stiffness and the incidence of diabetic kidney disease (DKD). Cumulative BP load enables the evaluation of long-term BP exposure, but the BP targets used to calculate it vary across studies. This study aimed to compare the predictive performance of cumulative BP load calculated using different clinically recommended BP targets. METHODS: This multicenter longitudinal study included participants with type 2 diabetes from 10 diabetes centers. Cumulative BP load was calculated using various clinically recommended BP targets (SBP < 140 mmHg, < 130 mmHg, and < 120 mmHg). The primary outcomes were the progression of arterial stiffness, assessed by brachial-ankle pulse wave velocity (ba-PWV) changes, and the incidence of DKD, defined as an estimated glomerular filtration rate < 60 mL/min/1.73m RESULTS: Among the 18,168 participants included (mean age 54.5 years; 57.5% male), 13,388 met all eligibility criteria for the analysis of arterial stiffness progression, and 11,145 for the analysis of DKD incidence. Over a mean follow-up of 3.5 years, the median ba-PWV increase was 0.19 m/s per year and 2,855 (25.6%) developed DKD. When cumulative BP load was added to a model containing traditional risk factors, the adjusted R
2. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0.
Using an updated Markov-based T1D Index, the authors estimate 9.5 million people living with type 1 diabetes in 2025, 513,000 incident cases, and 174,000 premature deaths (17.2% from non-diagnosis), projecting 14.7 million by 2040. Substantial data gaps remain in 119 countries and life expectancy varies widely, underscoring urgent needs for diagnosis, access, and surveillance.
Impact: Provides the most comprehensive and current global estimates for T1D to inform policy, resource allocation, and advocacy, with quantification of preventable deaths from non-diagnosis.
Clinical Implications: Strengthen early diagnosis pathways, ensure insulin and monitoring access, and prioritize registry/surveillance systems, particularly in low-income settings where prevalence and diagnostic gaps are growing fastest.
Key Findings
- Estimated 9.5 million people living with T1D in 2025, a 13% increase since 2021; projection to 14.7 million by 2040.
- Estimated 513,000 incident cases and 174,000 premature deaths in 2025, with 17.2% of deaths due to non-diagnosis shortly after onset.
- Life expectancy for a 10-year-old diagnosed in 2025 varies from 6 to 66 years across countries; no contemporary data for 119 countries.
Methodological Strengths
- Updated Markov model integrating incidence, adult incidence, mortality, and prevalence with recent population-based studies.
- Global coverage across 202 countries with transparent extrapolation for data-scarce settings.
Limitations
- Model-based estimates rely on data quality and assumptions; uncertainty is higher in countries without contemporary studies.
- Not designed to evaluate specific interventions or health system determinants causing geographic variability.
Future Directions: Build national T1D registries, improve case ascertainment, and link estimates to costed health system interventions to reduce non-diagnosis mortality and improve life expectancy.
AIMS: Globally, symptomatic type 1 diabetes (T1D) prevalence varies markedly. The International Diabetes Federation 11thEdition Atlas/T1D Index Version 3.0 estimated 2025 numbers for 202 countries/territories ("countries"), and projected to2040. METHODS: The T1D Index model, a Markov model with sub-models for incidence-over-time, adult incidence, and mortality-over-time, was updated with recent population-based T1D incidence, mortality and prevalence studies. For countries without studies, data were extrapolated from countries with similarsettings. RESULTS: There are estimated 9.5 million people living with T1D globally (compared to 8.4 million in 2021, a 13 % increase), with 1.0 million of these aged 0-14, and 0.8 million aged 15-19 years. In lower-income countries, prevalent cases increased by 20 % from 1.8 million in 2021 to 2.1 million in 2025. Incident cases in 2025 are an estimated 513,000 (164,000 aged 0-14 and 58,000 aged 15-19 years), with incidence increasing by 2.4 % in the last year. Premature deaths are estimated at 174,000, with 17.2 % of these due to non-diagnosis soon after clinical onset. The estimated remaining life expectancy of a 10-year-old child diagnosed with T1D in 2025 varies between countries from 6 to 66 years. There are still no data available for 119 countries. The projectedT1D population for 2040 is estimated to be14.7 million. CONCLUSIONS: The number of global T1D cases is rising quickly, especially in lower-income settings, due to increasing diagnosed incidence, falling mortality and ageing, and population growth. Contemporary data are unavailable for over 50% of all countries, highlighting need for epidemiological studies.
3. A novel nonsense mutation of the glucocorticoid receptor gene causing glucocorticoid resistance with infertility.
A male with Chrousos syndrome harbored a novel NR3C1 nonsense mutation (Y613) that truncates the ligand-binding domain, reducing dexamethasone affinity, nuclear translocation, and transactivation. STUB1 (CHIP) promoted ubiquitin–proteasome degradation of the truncated receptor; low STUB1 expression in testis/Sertoli cells suggests tissue-specific accumulation, providing a mechanistic link to infertility.*
Impact: Elucidates a genotype-to-phenotype mechanism in glucocorticoid resistance, integrating receptor biochemistry with tissue-specific proteostasis to explain male infertility.
Clinical Implications: Consider NR3C1 genetic testing in suspected glucocorticoid resistance with reproductive issues; awareness of tissue-specific proteostatic effects may inform tailored glucocorticoid dosing and future therapies targeting STUB1–proteasome pathways.
Key Findings
- Identification of a novel NR3C1 nonsense mutation (c.1839T>A, p.Tyr613Ter) in a male with oligospermia and infertility.
- GR Y613* shows reduced dexamethasone affinity, impaired nuclear translocation, and decreased transactivation; protein levels fall despite unchanged mRNA.
- STUB1 E3 ligase mediates ubiquitin–proteasome degradation of GR Y613*; low STUB1 expression in testis/Sertoli cells suggests tissue-specific receptor accumulation.
Methodological Strengths
- Functional validation combining receptor pharmacology, nuclear trafficking, and transactivation assays.
- Proteomic and cellular evidence linking STUB1-mediated ubiquitination to receptor degradation; tissue expression analysis across human datasets.
Limitations
- Single-patient genetic finding with in vitro validation; absence of in vivo functional or fertility rescue studies.
- Generalizability to broader Chrousos syndrome phenotypes remains to be established.
Future Directions: Expand to multi-patient cohorts with NR3C1 variants, assess testis-specific proteostasis in vivo, and explore STUB1 modulation as a therapeutic strategy for glucocorticoid resistance–associated infertility.
PURPOSE: Chrousos syndrome is a rare disease mainly caused by inactivated mutations in the NR3C1 gene, which encodes the human glucocorticoid receptor (GR). We reported a male patient of Chrousos syndrome, who had a novel nonsense mutation (c.1839T > A, p. Tyr613Ter) in NR3C1 and presented with oligospermic and infertility but without other typical clinical manifestation. The aim of this study is to explore the molecular mechanisms that cause the unique clinical manifestations in this patient. METHODS: Mutant plasmids were transfected to HEK293T and HeLa cells to evaluate glucocorticoid sensitivity and GR expression. Proteomic and further cellular experiments were used to illustrate the mechanism of GR expression change induced by mutation. RESULTS: The mutation causes the deletion of the ligand-binding region of the GR (GR Y613*). Compared with GR wild type (GR WT), GR Y613* had a decreased affinity with dexamethasone, reduced nuclear translocation and decreased transactivation of the glucocorticoid response gene mouse mammary tumor virus promoter. GR Y613* caused decreased protein but unchanged gene expression. E3 ligase STUB1 was identified to regulate ubiquitin-proteasome degradation of GR Y613*. Compared with other human tissues and cell types, expression of STUB1 in testis and Sertoli cells was low. CONCLUSIONS: GR Y613* causes reduced sensitivity to glucocorticoids. STUB1 promotes ubiquitination and degradation of GR Y613*. Low expression of STUB1 in human testis compared with other tissue might cause accumulation of GR Y613*, as a potential explanation of the infertility of Chrousos syndrome.